HC Wainwright Analysts Lower Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at HC Wainwright cut their Q2 2025 EPS estimates for Harrow in a note issued to investors on Monday, May 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $0.03 for the quarter, down from their previous forecast of $0.09. HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow's Q4 2025 earnings at $0.10 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). The firm had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%.

Separately, B. Riley lowered their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Harrow Stock Performance

Shares of HROW opened at $26.66 on Tuesday. The company's 50 day moving average price is $24.80 and its 200 day moving average price is $32.36. Harrow has a 52 week low of $11.39 and a 52 week high of $59.23. The company has a market capitalization of $978.02 million, a PE ratio of -28.36 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Institutional Investors Weigh In On Harrow

Several institutional investors and hedge funds have recently bought and sold shares of HROW. Braidwell LP increased its holdings in Harrow by 106.3% in the 4th quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after buying an additional 467,401 shares during the period. JPMorgan Chase & Co. increased its holdings in Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after buying an additional 194,480 shares during the period. Two Sigma Investments LP increased its holdings in Harrow by 483.2% in the 4th quarter. Two Sigma Investments LP now owns 150,355 shares of the company's stock valued at $5,044,000 after buying an additional 124,574 shares during the period. Neuberger Berman Group LLC increased its holdings in Harrow by 128.0% in the 4th quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company's stock valued at $6,728,000 after buying an additional 112,588 shares during the period. Finally, Trexquant Investment LP grew its holdings in shares of Harrow by 1,806.8% in the 4th quarter. Trexquant Investment LP now owns 94,500 shares of the company's stock worth $3,170,000 after purchasing an additional 89,544 shares during the last quarter. Institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.